NCT07699016 Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)
| NCT ID | NCT07699016 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Milan |
| Condition | Hemostasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2026-07-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2026-07-01 with a primary completion date of 2026-07-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making. HAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.
Eligibility Criteria
Inclusion Criteria: * Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents * Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months) * Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire Exclusion Criteria: * Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals) * Surgeons not involved in operative cardiovascular practice during the study period * External collaborators or visiting surgeons without regular clinical activity at the institution * Individuals who do not provide informed consent for participation in the anonymous survey * Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07699016 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemostasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07699016 currently recruiting?
Yes, NCT07699016 is actively recruiting participants. Contact the research team at luca.galassi@unimi.it for enrollment information.
Where is the NCT07699016 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07699016 clinical trial?
NCT07699016 is sponsored by University of Milan. The trial plans to enroll 15 participants.